Commentary: Interferon-y for treating Crohn's disease: do we know what is helpful and what is harmful?

Italian Journal of Gastroenterology and Hepatology

Volumn 29, Issue 5, 1997, Pages 406-408

  Pallone, F ^a,b   Fais, S ^a,b   Monteleone, G ^a,b  

^a UNIVERSITY MEDITERRANEA OF REGGIO CALABRIA   (Italy)

^b Policlinico Universitario   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; STEROID; TUMOR NECROSIS FACTOR ALPHA;

CASE REPORT; CELLULAR IMMUNITY; CROHN DISEASE; HUMAN; IMMUNOCOMPETENT CELL; MACROPHAGE ACTIVATION; NATURAL KILLER CELL; SHORT SURVEY; T LYMPHOCYTE;

CROHN DISEASE; HUMANS; INTERFERON-GAMMA, RECOMBINANT;

EID: 0031415445     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Isaacs KL, Sartor B, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
2. McAlindon ME, Mahida YR. Pro-inflammatory cytokines in inflammatory bowel disease. Aliment Pharmacol Therapeut 1996;10(Suppl. 2):72-4.
3. Pallone F, Monteleone G. Regulatory cytokines in inflammatory bowel disease. Aliment Pharmacol Therapeut 1996;10(Suppl. 2):75-9.
4. Van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tygat GNJ, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995 ; 109:129-35.
5. Van Deventer SJH, Camoglio L. Monoclonal antibody therapy of inflammatory bowel disease. Aliment Pharmacol Therapeut 1996;10(Suppl. 2):107-11.
6. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein. N EngI J Med 1997;337:141-7.
7. Debinski H, Forbes A, Kamm MA. Low dose of interferon gamma for refractory Crohn's disease. Ital J Gastroenterol Hepatol 1997;29:403-8.
8. Farrar MA, Schreiber RD. The molecular cell biology of interferon-y and its receptor. Annu Rev Immunol 1993;! 1:571-611.
9. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol 1988;141:2407-12.
10. Schreiber RD. Validation of a role for endogenously produced IFN-Y in resolution of Listeria monocytogenes infection in mice. In: Host defenses and immunomodulation to intracellular pathogens. Eisenstein TK, Hana N, Bullock WE, editors. Philadelphia: Plenum, 1986.
11. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991:324:509-16.
12. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barrai A, et al. Treatment of visceral Leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990:322:16-21.
13. Pallone F, Fais S, Boirivant M. The interferon system in inflammatory bowel disease. In: Fiocchi C, editor. Cytokines in Inflammatory Bowel Disease. R.G. Landes Company, 1995:57-67.
14. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT. Interleukin-2- and interferon-y secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993:78:127-31.
15. Fais S, Capobianchi MR, Pallone F, Di Marco P, Boirivant M, Dianzani F, et al. Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. Gut 1991:32:403-7.
16. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, -4 o\. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-y, whereas Ulcerative Colitis LP cells manifest increased secretion of IL-5. J Immunol 1996:157:1261-70.
17. Fais S, Pallone F. Ability of human colonie epithelium to express the 4F2 antigen, CALLA and the transferrin receptor. Studies in inflammatory bowel disease and after exposure to different stimuli. Gastroenterology 1989;97:1436-41.
18. Pallone F, Fais S, Capobianchi MR. HLA-D region antigens on isolated human colonie epithelial cells: enhanced expression in inflammatory bowel disease and in vitro induction by different stimuli. Clin Exp Immunol 1988;74:75-9.
19. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O; Luzza F, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997; 112:1169-78.
20. Trinchieri G. Interleukin-12; a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-Helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4006-27.
21. Yoshida T, Higa A, Sakamoto H, Daimon Y, Ohashi T, Haraguchi Y, et al. Immunological and clinical effects of interferon gamma on Crohn's disease. J Clin Lab Immunol 1988;25:105-8.
22. Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CDS effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994;1180:1715-28.
23. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994;12:635-73.
24. Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997; 113:118-26.